Pai Vasudev B, Tai Cheh Kuan, Bhakri Kunal, Kolvekar Shyam
Department of Cardiothoracic Surgery, Heart Hospital , University College London Hospital, London, UK.
Interact Cardiovasc Thorac Surg. 2012 Aug;15(2):240-3. doi: 10.1093/icvts/ivs115. Epub 2012 May 2.
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether a mechanical or bioprosthetic valve is superior for immediate and long-term survival in patients with end-stage renal disease (ESRD) undergoing a valve replacement. Altogether more than 150 papers were found using the reported search; of which, eight represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. There were no randomized controlled trials addressing the question. There was one systematic review and meta-analysis. All the other evidence was in the form of retrospective studies. The papers show that there is no significant difference in the results and survival between patients receiving a mechanical and those receiving a bioprosthetic valve. This was seen in the meta-analysis as well as the larger series of patients who underwent valve replacement. Bleeding complications were more common with mechanical valves. We conclude that the choice of valve for patients with ESRD should be determined by age, level of activity and patient choice. Due to the limited life expectancy of these patients, bioprosthetic valves should be considered, especially since there is no evidence of early degeneration of tissue valves in this subgroup of patients.
一篇心脏外科的最佳证据主题文章是按照结构化方案撰写的。所探讨的问题是,对于终末期肾病(ESRD)患者在进行瓣膜置换时,机械瓣膜或生物瓣膜在即刻和长期生存方面是否更具优势。通过报告的检索共找到150多篇论文;其中,八篇代表了回答该临床问题的最佳证据。这些论文的作者、期刊、发表日期和国家、所研究的患者群体、研究类型、相关结局和结果都列成了表格。没有针对该问题的随机对照试验。有一项系统评价和荟萃分析。所有其他证据均为回顾性研究形式。这些论文表明,接受机械瓣膜和接受生物瓣膜的患者在结果和生存方面没有显著差异。这在荟萃分析以及接受瓣膜置换的更多患者系列中都有体现。机械瓣膜的出血并发症更为常见。我们得出结论,ESRD患者瓣膜的选择应根据年龄、活动水平和患者的选择来决定。由于这些患者的预期寿命有限,应考虑使用生物瓣膜,特别是因为在该亚组患者中没有证据表明组织瓣膜会早期退化。